Beyond the Abstract - Degarelix: A new approach for the treatment of prostate cancer, by Bo-Eric Persson, MD
BERKELEY, CA (UroToday.com) - Gonadotrophin-releasing hormone (GnRH) agonists are currently the ‘standard of care’ for androgen deprivation therapy (ADT) in prostate cancer.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
